Lenz Therapeutics Announces FDA Approval of Vizz for the Treatment of Presbyopia - Top-Institutions - MDSpire

Lenz Therapeutics Announces FDA Approval of Vizz for the Treatment of Presbyopia

Near vision improvements were demonstrated within 30 minutes and lasted up to 10 hours in clinical trials.

  • July 8, 2025

  • 2 min

Share

Top Institutions in Ophthalmology

Brief introduction explaining scope and methodology.

  • #1

    Bascom Palmer Eye Institute
    Bascom Palmer Eye Institute

    Miami, FL

    Key Differentiators

    • Ophthalmology
    • Vision Research
    • Clinical Trials

  • #2

    Massachusetts Eye and Ear Infirmary
    Massachusetts Eye and Ear Infirmary

    Boston, MA

    Key Differentiators

    • Ophthalmology
    • Cornea and External Disease
    • Clinical Research

  • #3

    Johns Hopkins Wilmer Eye Institute
    Johns Hopkins Wilmer Eye Institute

    Baltimore, MD

    Key Differentiators

    • Ophthalmology
    • Vision Science
    • Clinical Trials

  • #4

    University of California, San Francisco (UCSF) Department of Ophthalmology
    University of California, San Francisco (UCSF) Department of Ophthalmology

    San Francisco, CA

    Key Differentiators

    • Ophthalmology
    • Clinical Trials
    • Vision Research

Original Source(s)

Lenz Therapeutics Announces FDA Approval of Vizz for the Treatment of Presbyopia

  • July 8, 2025

Related Content

FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia

Deseyne delivers smooth, continuous focus across near, intermediate, and distance vision, which is enabled by Cataltheia’s patented hyper-refractive central zone, engineered to precisely redirect light in a controlled manner.

Equal Pay in Ophthalmology? Not Yet

A decade of AAMC salary data reveals a persistent gender pay gap in academic ophthalmology—and projects it will never close at senior ranks

Therapeutic Focus: <em>Drop</em>ping Some Knowledge

Vizz (aceclidine ophthalmic solution) 1.44%, from Lenz Therapeutics, offers spectacle-free vision and the opportunity to secure patient loyalty.